利尔化学股份有限公司 独立董事工作制度 第一章 总则 第一条 为进一步完善利尔化学股份有限公司（以下简称"公司"）治理结 构，促进公司规范运作，依据《中华人民共和国公司法》、《中华人民共和国证券 法》、中国证券监督管理委员会（以下简称"中国证监会"）《上市公司独立董事 管理办法》等法律、法规和《公司章程》的有关规定，制定本制度。 第二条 独立董事是指不在公司担任除董事外的其他职务，并与公司及其主 要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独 立客观判断关系的董事。 独立董事应当独立履行职责，不受公司及其主要股东、实际控制人等单位或 者个人的影响。 第三条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证监会规定、深圳证券交易所（以下简称"深交所"）业务规则 和公司章程的规定，认真履行职责，在董事会中发挥参与决策、监督制衡、专业 咨询作用，维护公司整体利益，保护中小股东合法权益。 第四条 公司独立董事占董事会成员的比例不得低于三分之一，且至少包括 一名会计专业人士。 公司审计委员会成员应当为不在公司担任高级管理人员的董事，其中独立董 事应当过半数，并由独立董 ...

利尔化学股份有限公司 证券代码：002258 证券简称：利尔化学 利尔化学股份有限公司投资者关系活动记录表 编号：2023-02 投资者关系活  特定对象调研 □分析师会议 动类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内 容） 参与单位名称 东北证券：陈俊杰、孙鹏程；景林资产：蒋文超；淳阳基金： 及人员姓名 周彪。 时间 2023年11月16日 地点 公司会议室 上市公司接待 副总经理/董事会秘书：刘军 人员姓名 董事会办公室：马媛 1、公司精草铵膦项目建设进展？ 答：湖南津市2万吨/年酶法精草铵膦项目已经投产， 生产情况正常；荆州1万吨/年生化法精草铵膦项目已于今 年上半年开始建设，建设进程顺利，预计明年内投产。 ...

Financial Performance - The company's revenue for Q3 2023 was ¥1,537,231,043.15, a decrease of 42.30% compared to the same period last year[5] - Net profit attributable to shareholders was ¥80,269,093.00, down 81.94% year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥72,707,752.04, reflecting an 83.24% decline compared to the previous year[5] - The total operating revenue for the third quarter of 2023 was CNY 6,006,422,528.32, a decrease of 22.4% compared to CNY 7,742,484,720.81 in the same period last year[18] - The net profit for Q3 2023 was CNY 707,628,843.99, a decrease of 57.7% compared to CNY 1,672,292,899.76 in Q3 2022[20] - Operating profit for Q3 2023 was CNY 831,453,910.63, down 58.3% from CNY 1,993,816,319.08 in the same period last year[20] - Revenue from sales of goods and services received in Q3 2023 was CNY 4,953,454,919.11, a decline of 23.1% from CNY 6,435,395,874.28 in Q3 2022[21] - The total profit for Q3 2023 was CNY 829,179,957.13, a decrease of 58.3% from CNY 1,981,137,142.83 in Q3 2022[20] - Basic earnings per share for Q3 2023 were CNY 0.6996, a decrease of 65.3% from CNY 2.0147 in Q3 2022[20] - The total comprehensive income for Q3 2023 was CNY 707,628,843.99, down 57.7% from CNY 1,672,292,899.76 in Q3 2022[20] Assets and Liabilities - The total assets at the end of the reporting period reached ¥14,002,280,821.62, an increase of 8.83% from the end of the previous year[5] - Total assets increased to CNY 14,002,280,821.62 from CNY 12,866,345,708.15, showing a growth of 8.8%[16] - Total liabilities rose to CNY 5,319,239,048.21 from CNY 4,483,335,442.13, an increase of 18.6%[16] - The company's non-current liabilities increased significantly to CNY 2,176,913,648.49 from CNY 885,372,764.13, marking a rise of 146.5%[16] Cash Flow - Cash flow from operating activities for the year-to-date was ¥337,935,268.23, a significant decrease of 80.84%[5] - The net cash flow from operating activities for Q3 2023 was CNY 337,935,268.23, a significant decrease of 81.9% compared to CNY 1,764,036,388.26 in Q3 2022[21] - The net cash flow from financing activities for Q3 2023 was CNY 933,970,558.58, compared to a net outflow of CNY 455,088,763.03 in Q3 2022[22] - Cash and cash equivalents decreased to CNY 1,100,717,665.72 from CNY 1,409,008,134.72, reflecting a decline of 21.8%[14] - Cash and cash equivalents at the end of Q3 2023 were CNY 1,079,179,442.83, a decrease from CNY 1,197,101,282.74 at the end of Q3 2022[22] Shareholder Information - The company’s major shareholders include Sichuan Jiuyuan Investment Holding Group Co., Ltd. with a 23.78% stake[11] - The company recorded a total of 54,082 common shareholders at the end of the reporting period[11] Operational Metrics - The total operating costs amounted to CNY 5,180,599,626.07, down from CNY 5,773,982,257.76, indicating a reduction of 10.3% year-over-year[18] - Accounts receivable decreased to CNY 1,295,562,611.55 from CNY 1,588,107,170.85, a reduction of 18.4%[15] - Inventory levels decreased to CNY 1,483,655,674.10 from CNY 1,709,758,816.00, representing a decline of 13.2%[15] - The company reported a 49.21% increase in prepayments, totaling ¥13,344.84 million, primarily due to increased operational prepayments[10] - Short-term borrowings increased by 110.73% to ¥27,915.89 million, attributed to new short-term loans taken during the period[10] Research and Development - Research and development expenses in Q3 2023 amounted to CNY 243,696,434.27, down 10.3% from CNY 271,644,374.07 in Q3 2022[20] - The company is focusing on expanding its market presence and developing new products, although specific figures were not disclosed in the report[15]

2023 年 10 月 24 日，利尔化学股份有限公司（以下简称"公司"） 第六届董事会第十二次会议以通讯表决的方式召开，会议通知于 2023 年 10 月 19 日以电子邮件方式送达。应出席会议的董事 9 人，实际出 席会议的董事 9 人。会议程序符合《公司法》和公司章程的规定。会议 由公司董事长尹英遂主持，经过各位董事认真审议，形成如下决议： 1、会议以 9 票同意，0 票弃权，0 票反对的结果，审议通过了《公 司 2023 年第三季度报告》。 证券代码：002258 证券简称：利尔化学 公告编号：2023-027 利尔化学股份有限公司 第六届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确 和完整，没有虚假记载、误导性陈述或重大遗漏。 特此公告。 利尔化学股份有限公司 董事会 2023 年 10 月 25 日 《公司 2023 年第三季度报告》刊登于 2023 年 10 月 25 日的中国 证券报和巨潮资讯网。 2、会议以 9 票同意，0 票弃权，0 票反对的结果，审议通过了《关 于公司内部组织机构调整的议案》。根据公司发展需要，为完善集团化 管控，会议同意公司设立生产运营 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥4,469,191,485.17, a decrease of 11.99% compared to ¥5,078,112,991.44 in the same period last year[24]. - The net profit attributable to shareholders was ¥479,689,916.47, down 54.21% from ¥1,047,583,941.10 year-on-year[24]. - The net cash flow from operating activities was ¥317,095,328.07, reflecting a significant decline of 75.54% compared to ¥1,296,536,529.40 in the previous year[24]. - Basic earnings per share decreased to ¥0.5993, down 57.74% from ¥1.4181 in the same period last year[24]. - The company reported a significant decrease in net profit after deducting non-recurring gains and losses, which was ¥481,350,115.74, down 54.19% from ¥1,050,698,840.97 year-on-year[24]. - The company's operating revenue for the reporting period was approximately ¥4.47 billion, a decrease of 11.99% compared to ¥5.08 billion in the same period last year, primarily due to a significant decline in the prices of core products[48]. - The company reported a total operating cost of CNY 3,741,055,116.65 for the first half of 2023, an increase of 1.5% compared to CNY 3,686,264,809.79 in the first half of 2022[167]. - The company’s financial expenses showed a significant improvement, with a net financial income of CNY 14,771,121.62 in the first half of 2023 compared to a loss of CNY 49,652,855.78 in the same period of 2022[168]. Assets and Liabilities - Total assets at the end of the reporting period were ¥13,590,819,972.61, an increase of 5.63% from ¥12,866,345,708.15 at the end of the previous year[24]. - The company's total liabilities increased to CNY 1,867,528,030.88 in the first half of 2023 from CNY 2,086,923,187.74 in the same period of 2022, representing a reduction of 10.5%[168]. - Long-term borrowings increased to ¥1,629,705,061.75, accounting for 11.99% of total liabilities, up from 4.35% last year[53]. - Total current assets decreased from CNY 5,157,349,061.32 to CNY 4,546,308,061.88, a decline of approximately 11.8%[159]. - Total non-current assets increased from CNY 7,708,996,646.83 to CNY 9,044,511,910.73, an increase of approximately 17.3%[161]. Market and Industry Trends - The global pesticide market size increased from $35.575 billion in 2006 to $87.7 billion in 2022, with a compound annual growth rate (CAGR) of approximately 5.80%[32]. - The domestic pesticide industry is undergoing significant transformation, with a focus on green pesticides and stricter environmental regulations[34]. - The company's main product, glyphosate, is experiencing a decline in price, impacting overall performance[36]. - The demand for the company's high-efficiency, low-toxicity pesticides is expected to rise due to the promotion of genetically modified crops[35]. - The integration of major international agricultural companies has led to a more concentrated market for upstream intermediates and active ingredients[33]. Research and Development - Research and development investment increased by 14.88% to approximately ¥201.76 million, reflecting the company's commitment to innovation[48]. - The company is focusing on strategic acquisitions to enhance its product offerings and market share in the chemical industry[181]. - The company has allocated 15.8 million for research and development in the first half of 2023, aiming to enhance product innovation[184]. Environmental Compliance - The company has established comprehensive waste treatment facilities to minimize negative environmental impacts[87]. - The company achieved compliance with emission standards for various pollutants, including 40.28 tons/year of sulfur dioxide and 163.73 tons/year of nitrogen oxides[92]. - The company has implemented a comprehensive environmental self-monitoring plan, with all monitoring data meeting national and local standards, and no instances of exceeding discharge limits reported[99]. - The company has made significant investments in emission control technologies to enhance environmental performance[92]. - The company has increased its environmental protection investments, ensuring compliance with stricter regulations, which may impact profitability[74]. Strategic Initiatives - The company plans to expand its market presence by launching new products and enhancing its research and development capabilities in the upcoming quarters[180]. - The company aims to mitigate foreign exchange risks through forward foreign exchange contracts, which resulted in losses due to significant fluctuations in the USD exchange rate during the reporting period[64]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[184]. Shareholder Information - The annual shareholders' meeting had a participation rate of 50.44% on March 22, 2023[80]. - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[82]. - The total number of common shareholders at the end of the reporting period is 58,262[147]. - The largest shareholder, Sichuan Jiuyuan Investment Holding Group Co., Ltd., holds 23.78% of the shares, totaling 190,376,009 shares[148]. Risk Factors - The company faces various risks including market competition, raw material supply and price fluctuations, and environmental risks, which investors should be aware of[5]. - Safety production risks remain a concern due to the nature of materials used in production, and the company emphasizes enhancing safety management and emergency response capabilities[75]. - Raw material costs significantly affect operating costs and gross margins, with increased supply but also rising procurement challenges due to demand fluctuations[72].

利尔化学股份有限公司 独立董事对有关事项的独立意见 经公司 2021 年度股东大会审议批准，同意公司为控股子公司四川利尔作物 1 根据《公司法》、《上市公司独立董事规则》、《深圳证券交易所股票上市规则》、 《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》、《公 司章程》及《公司独立董事工作制度》等相关法律、法规、规范性文件的有关规 定，作为公司的独立董事，经过审慎、认真的研究，现基于独立判断立场对有关 事项发表意见如下： 对公司关联方资金占用和对外担保的专项说明和独立意见 根据中国证监会、深圳证券交易所及公司治理制度等有关规定和要求，作为 公司的独立董事，我们本着对公司、全体股东负责的态度，对公司控股股东及其 他关联方占用公司资金情况和对外担保情况进行了认真的核查，现发表如下独立 意见： 1、报告期内，公司与控股股东及其他关联方的资金往来能够严格遵守相关 规定，不存在关联方违规占用公司资金的情况。 2、经公司 2020 年年度股东大会审议批准，同意公司为全资子公司广安利 尔化学有限公司（以下简称"广安利尔"）向银行申请的 6.32 亿元基本授信提供连 带责任担保。2021 年 4 月 8 ...

2023年1-6月非经营性资金占用及其他关联资金往来情况汇总表 上市公司名称：利尔化学股份有限公司 单位：万元 1 企业负责人： 尹英遂 主管会计工作的负责人： 颜宣 会计机构负责人： 羊晓莉 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 | 上市公司核算的会计 | 2023年期初占用资金 | 2023年1-6月占用累 | 2023年1-6月占用资 | 2023年1-6月偿还累 | 2023年6月末占用资 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关联关系 | 科目 | 余额 | 计发生金额（不含利 息） | 金的利息(如有） | 计发生金额 | 金余额 | | | | | | | | | | | | | | 非经营性占用 | | 控股股东、实际控制人及 其附属企业 | | | | | | | | | | 非经营性占用 | | | | | | | | | | | | 非经营性占用 | | 小计 | - | - | - | - | - | - | - ...

利尔化学股份有限公司 证券代码：002258 证券简称：利尔化学 利尔化学股份有限公司投资者关系活动记录表 编号：2023-01 投资者关系活动 特定对象调研 □分析师会议 类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 海通证券：李智；四川发展证券基金：肖柏辰；弘尚资产：沙 人员姓名 正江；申万资管：许维伦；华能贵诚信托：赵文 时间 2023 年 7 月 19 日 地点 公司会议室 上市公司接待人 副总经理/董事会秘书：刘军 员姓名 董事会办公室：马媛 1、公司如何看待草铵膦市场？ 答：今年以来受竞争加剧以及农化行业周期的影响，公司 主要产品草铵膦价格下降较大，对公司业绩产生了较大的影 响。公司一直都看好草铵膦市场的成长空间，并全力保持竞争 优势。 2、公司精草铵膦项目的实施情况？ 答：目前公司正在按照建设计划有序推进，湖南津市 2 万 投资者关系活动 吨/年酶法精草铵膦项目预计 7 月开始试生产，荆州 1 万吨/ 主要内容介绍 年生化法精草铵膦项目已于今年 2 月获批开建。同时，公司加 快实施精草铵膦在海外多个国家的登记和市场布局工 ...

Financial Performance - The company's revenue for Q1 2023 was ¥2,442,238,961.34, a decrease of 6.53% compared to ¥2,612,935,661.17 in the same period last year[5] - Net profit attributable to shareholders was ¥274,738,068.68, down 48.58% from ¥534,331,688.15 year-on-year[5] - Basic earnings per share fell by 52.63% to ¥0.3432 from ¥0.7245 in the same period last year[5] - In Q1 2023, the net profit of Lier Chemical Co., Ltd. was CNY 342,029,168.28, a decrease of 42.2% compared to CNY 591,086,437.05 in Q1 2022[20] - The company's operating profit for Q1 2023 was CNY 403,195,762.83, down 42.6% from CNY 700,540,696.90 in the same period last year[20] - Total comprehensive income attributable to the parent company was CNY 274,738,068.68, down 48.6% from CNY 534,331,688.15 in Q1 2022[21] - Basic earnings per share for Q1 2023 were CNY 0.3432, a decrease of 52.6% from CNY 0.7245 in the same quarter last year[21] Cash Flow and Investments - The net cash flow from operating activities decreased by 39.47% to ¥123,955,733.40 from ¥204,771,003.87 in the previous year[5] - Cash flow from operating activities for Q1 2023 was CNY 123,955,733.40, a decline of 39.3% compared to CNY 204,771,003.87 in Q1 2022[22] - The company reported a net cash outflow from investing activities of CNY 703,479,356.00, worsening from CNY 309,682,113.96 in the previous year[23] Assets and Liabilities - Total assets increased by 6.20% to ¥13,663,798,916.24 compared to ¥12,866,345,708.15 at the end of the previous year[5] - Total liabilities increased to CNY 5,360,897,789.58 from CNY 4,483,335,442.13, an increase of 19.5%[18] - The company's equity attributable to shareholders decreased to CNY 7,148,862,668.32 from CNY 7,269,668,905.14, a decline of 1.7%[18] Operating Costs and Expenses - The total operating costs increased to CNY 2,044,281,131.94, up 6.5% from CNY 1,919,660,705.54 year-on-year[19] - The company incurred financial expenses of CNY 29,987,879.75, an increase of 21.1% from CNY 24,730,210.15 in Q1 2022[20] Research and Development - The company's R&D expenses rose by 55.49% to ¥9,752.61 from ¥6,272.32 in the previous year, indicating increased investment in innovation[11] - Research and development expenses increased to CNY 97,526,071.23, up 55.5% from CNY 62,723,198.01 in Q1 2022[20] Shareholder Information - The company recorded a total of 58,015 common shareholders at the end of the reporting period[12] Other Financial Metrics - The weighted average return on equity decreased to 3.71% from 10.19% in the previous year, indicating a decline in profitability[5] - The company reported a net profit margin decline due to increased costs, impacting overall profitability[19] - Cash and cash equivalents at the end of Q1 2023 were CNY 1,353,582,752.50, slightly down from CNY 1,333,738,748.44 at the end of Q1 2022[23] - Accounts receivable rose to CNY 1,628,660,818.38 from CNY 1,588,107,170.85 at the start of the year, indicating a growth of 2.3%[16] - Inventory decreased to CNY 1,642,894,394.51 from CNY 1,709,758,816.00, reflecting a decline of 3.9%[17] - Short-term borrowings increased significantly to CNY 295,209,305.55 from CNY 132,475,216.16, marking a rise of 123.5%[18] - The company reported a significant increase in prepayments, which rose by 63.34% to ¥14,608.30, primarily due to increased procurement of raw materials[11]

证券代码：002258 证券简称：利尔化学 公告编号：2023-010 利尔化学股份有限公司 关于举行 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 利尔化学股份有限公司（以下简称"公司"）已于2023年3月2日在 巨潮资讯网（www.cninfo.com.cn）上披露了《2022年年度报告》。 为使投资者更深入、全面地了解公司2022年度报告的内容，公司拟 于2023年3月21日（星期二）15:00-17:00举行2022年度网上业绩说 明会。 本次年度业绩说明会将采用网络远程的方式举行，投资者可登陆 深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn），进入 "云访谈"栏目参与本次年度业绩说明会。 公司拟出席本次年度业绩说明会的人员有：公司董事长尹英遂先 生，独立董事李双海先生，副总经理、董事会秘书刘军先生，财务负 责人、财务总监颜宣先生。（如有特殊情况，参会人员可能进行调整。） 为充分尊重投资者、提升交流的针对性，现就公司2022年度业 绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和 ...